Dlb

Latest News for: dlb

Edit

150 applicants with disabilities raise recruitment concerns at DLB office

The Times of India 22 Sep 2026

Edit

CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB) (Form 8-K) (Cervomed Inc)

Public Technologies 14 Jul 2026

CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB) ... BF atrophy is the primary pathogenic driver of disease expression and progression in DLB.

Edit

CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB) (Cervomed Inc)

Public Technologies 14 Jul 2026

BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB).

Article Search

tools

You can search using any combination of the items listed below.

Language:

Sort:

Indexed:

Search:

Duplicates:

Podcasts:

Latest News for: dlb

150 applicants with disabilities raise recruitment concerns at DLB office

CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB) (Form 8-K) (Cervomed Inc)

CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB) (Cervomed Inc)

Article Search

EXPLORE WN.com